This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: ADC Therapeutics (ADCT), Bristol-Myers Squibb (BMY)

Tipranks - Tipranks - Sat Jun 6, 12:12PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ADC Therapeutics (ADCT) and Bristol-Myers Squibb (BMY) with bullish sentiments.

Claim 55% Off TipRanks

ADC Therapeutics (ADCT)

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on ADC Therapeutics, with a price target of $10.00. The company’s shares closed last Friday at $1.14.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 27.2% and a 52.8% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as ArriVent BioPharma, Inc., Zentalis Pharmaceuticals, and Monte Rosa Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADC Therapeutics with a $6.25 average price target, which is a 359.6% upside from current levels. In a report released yesterday, Stephens also assigned a Buy rating to the stock with a $5.00 price target.

See the top stocks recommended by analysts >>

Bristol-Myers Squibb (BMY)

In a report released today, Seamus Fernandez from Guggenheim maintained a Buy rating on Bristol-Myers Squibb, with a price target of $72.00. The company’s shares closed last Friday at $57.60.

According to TipRanks.com, Fernandez is a 5-star analyst with an average return of 23.5% and a 59.2% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Sagimet Biosciences, Inc. Class A, and Mineralys Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $62.94 average price target, implying a 10.4% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $70.00 price target.

Read More on ADCT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).